NEW YORK, NY / ACCESSWIRE / June 22, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

GRPN Shareholders Click Here: https://www.zlk.com/pslra-1/groupon-inc-loss-form?prid=7484&wire=1
ENDP Shareholders Click Here: https://www.zlk.com/pslra-1/endo-international-plc-loss-submission-form?prid=7484&wire=1
CEMI Shareholders Click Here: https://www.zlk.com/pslra-1/chembio-diagnostics-inc-loss-submission-form?prid=7484&wire=1

* ADDITIONAL INFORMATION BELOW *

Groupon, Inc. (GRPN)

GRPN Lawsuit on behalf of: investors who purchased November 4, 2019 - February 18, 2020
Lead Plaintiff Deadline: June 29, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/groupon-inc-loss-form?prid=7484&wire=1

According to the filed complaint, during the class period, Groupon, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing fewer customer engagements in its Goods category; (2) Groupon relied on its Goods category to drive its sales, especially during the holiday season; (3) as a result of the foregoing, the Company was likely to experience reduced sales; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Endo International Plc (ENDP)

ENDP Lawsuit on behalf of: investors who purchased August 8, 2017 - June 10, 2020
Lead Plaintiff Deadline: August 18, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/endo-international-plc-loss-submission-form?prid=7484&wire=1

According to the filed complaint, during the class period, Endo International Plc made materially false and/or misleading statements and/or failed to disclose that: (i) Endo's and/or its subsidiaries' contributions to the opioid crisis (including, but not limited to, their opioid products' disproportionately negative impact on New York and the fraud that Defendants perpetrated on the New York insurance market) were larger in scope than the Company had represented; (ii) part of that contribution to the crisis included Endo publishing and disseminating false information to health care providers regarding the risks and benefits of opioids; (iii) the foregoing, once revealed, was foreseeably likely to subject Endo and/or its subsidiaries to increased regulatory scrutiny and enforcement, as well as significant financial and/or reputational harm, particularly with respect to New York; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.